Gene Therapy Pioneer Jim Wilson Comments on Solid Biosciences’s Announcement of FDA IND Clearance for Friedreich’s Ataxia Treatment

PHILADELPHIA, Jan. 8, 2025 /PRNewswire/ — Today, Dr. Jim Wilson, President and CEO of GEMMA Biotherapeutics (“GEMMABio”) commented on Solid Bioscience’s announcement of clearance by the Food and Drug Administration for its Investigational New Drug (IND) to treat Friedreich’s ataxia (FA):…